Moleculin Biotech Files 2023 10-K, Details Financials and Warrant Adjustments

TL;DR

<b>Moleculin Biotech's 2023 10-K details warrant adjustments and financial reporting for the fiscal year.</b>

AI Summary

Moleculin Biotech, Inc. (MBRX) filed a Annual Report (10-K) with the SEC on March 22, 2024. Moleculin Biotech, Inc. filed its 2023 10-K on March 22, 2024, reporting on its fiscal year ending December 31, 2023. The filing details warrant adjustments due to stock splits, including specific exercise prices and expiration dates for outstanding warrants. For instance, warrants to purchase 7,892 shares at $181.80 expired December 22, 2023, and warrants for 365 shares at $208.80 expired June 21, 2023. The company's address is 5300 Memorial Drive, Suite 950, Houston, TX 77007, with a phone number of 713-300-5160. The filing includes information on common stock, additional paid-in capital, retained earnings, and accumulated other comprehensive income for fiscal years 2021, 2022, and 2023.

Why It Matters

For investors and stakeholders tracking Moleculin Biotech, Inc., this filing contains several important signals. Investors can review the company's financial health and capital structure, including changes in equity accounts and the impact of stock splits on outstanding warrants. The specific details on warrant adjustments are crucial for understanding potential dilution and the effective exercise prices for current and future warrant holders.

Risk Assessment

Risk Level: medium — Moleculin Biotech, Inc. shows moderate risk based on this filing. The company's financial disclosures, particularly regarding warrants and stock splits, indicate a complex capital structure and potential for significant adjustments that could impact share value and dilution.

Analyst Insight

Monitor future filings for updates on warrant expirations, exercise activity, and any further stock split or recapitalization events that could affect share structure.

Key Numbers

• 7,892 — Shares under warrant (Warrants expiring December 22, 2023)
• 365 — Shares under warrant (Warrants expiring June 21, 2023)
• $181.80 — Exercise price (Warrants expiring December 22, 2023)
• $208.80 — Exercise price (Warrants expiring June 21, 2023)

Key Players & Entities

• Moleculin Biotech, Inc. (company) — Filer name
• 5300 Memorial Drive, Suite 950, Houston, TX 77007 (address) — Business and mailing address
• 713-300-5160 (phone) — Business phone number
• December 31, 2023 (date) — Fiscal year end
• March 22, 2024 (date) — Filing date
• December 22, 2023 (date) — Warrant expiration date
• June 21, 2023 (date) — Warrant expiration date

FAQ

Risk Factors

• Warrant Adjustments and Dilution [medium — financial]: The company's warrant agreements include provisions for adjustments to exercise prices and share counts in the event of stock splits, recapitalizations, or other corporate actions, which can impact the potential dilution for existing shareholders.

Key Dates

• 2023-12-31: Fiscal Year End — Reporting period for the 10-K
• 2024-03-22: 10-K Filing Date — Date the annual report was submitted to the SEC

Glossary

10-K

An annual report required by the U.S. Securities and Exchange Commission (SEC), which gives a comprehensive summary of a company's financial performance. (Provides a detailed overview of the company's financial condition and business operations for the fiscal year.)

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share MBRX Nasdaq Stock Market

Filing Documents

• mbrx20231231_10k.htm (10-K) — 1817KB
• ex_597487.htm (EX-23.1) — 3KB
• ex_597488.htm (EX-31.1) — 12KB
• ex_597489.htm (EX-31.2) — 12KB
• ex_597490.htm (EX-32.1) — 5KB
• ex_597491.htm (EX-32.2) — 5KB
• ex_637480.htm (EX-97) — 25KB
• 0001437749-24-009044.txt (&nbsp;) — 7637KB
• mbrx-20231231.xsd (EX-101.SCH) — 67KB
• mbrx-20231231_cal.xml (EX-101.CAL) — 51KB
• mbrx-20231231_def.xml (EX-101.DEF) — 445KB
• mbrx-20231231_lab.xml (EX-101.LAB) — 414KB
• mbrx-20231231_pre.xml (EX-101.PRE) — 476KB
• mbrx20231231_10k_htm.xml (XML) — 1122KB

Business

Item 1. Business 3

Risk Factors

Item 1A. Risk Factors 27

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 47

Cybersecurity

Item 1C. Cybersecurity 48

Properties

Item 2. Properties 49

Legal Proceedings

Item 3. Legal Proceedings 49

Mine Safety Disclosure

Item 4. Mine Safety Disclosure 49 PART II

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 50

[Reserved]

Item 6. [Reserved] 50

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 51

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 56

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 56

Change in and Disagreements with Accountants on Accounting and Financial Disclosures

Item 9. Change in and Disagreements with Accountants on Accounting and Financial Disclosures 56

Controls and Procedures

Item 9A. Controls and Procedures 57

Other Information

Item 9B. Other Information 57

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 57 PART III I tem 10. Directors, Executive Officers and Corporate Governance 58

Executive Compensation

Item 11. Executive Compensation 58

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 58

Certain Relationships and Related Transactions and Director Independence

Item 13. Certain Relationships and Related Transactions and Director Independence 58

Principal Accountant Fees and Services

Item 14. Principal Accountant Fees and Services 58 PART IV

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 58

Form 10-K Summary

Item 16. Form 10-K Summary 61

Signatures

Signatures 62 1 Table of Contents Moleculin Biotech, Inc. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS The Securities and Exchange Commission, referred to herein as the SEC, encourages companies to disclose forward-looking information so that investors can better understand a company's future prospects and make informed investment decisions. Certain statements that we may make from time to time, including, without limitation, statements contained in this report constitute "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We make forward-looking statements under the "Risk Factors," "Business," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and in other sections of this report. In some cases, you can identify these statements by forward-looking words such as "may," "might," "should," "would," "could," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or "continue," and the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. In particular, you should consider the numerous risks and uncertainties described under "Risk Factors." While we believe we have identified material risks, these risks and uncertainties are not exhaustive. Other sections of this report describe additional factors that could adversely imp

Forward-looking statements include, but are not limited to, statements about

Forward-looking statements include, but are not limited to, statements about: Our ability to continue our relationship with MD Anderson, including, but not limited to, our ability to maintain current licenses and license future intellectual property resulting from our sponsored research agreements with MD Anderson; The success or the lack thereof, including the ability to recruit subjects on a timely basis, for a variety of reasons, of our clinical trials through all phases of clinical development; Our ability to satisfy any requirements imposed by the United States (US) Food and Drug Administration (FDA) (or its foreign equivalents) as a condition of our clinical trials proceeding or beginning as planned; World-wide events including the war in Ukraine and in Israel, the COVID-19 pandemic, and the general supply chain shortages effect on our clinical trials, clinical drug candidate supplies, preclinical activities and our ability to raise future financing; Our ability to obtain additional funding to commence or continue our clinical trials, fund operations and develop our product candidates; The need to obtain and retain regulatory approval of our drug candidates, both in the United States and in Europe, and in countries deemed necessary for future trials; Our ability to complete our clinical trials in a timely fashion and within our expected budget and resources; Our ability to source our drug products at reasonable prices; Compliance with obligations under intellectual property licenses with third parties; Any delays in regulatory review and approval of drug candidates in clinical development; Potential efficacy of our drug candidates; Our ability to commercialize our drug candidates; Market acceptance of our drug candidates; Competition from existing therapies or new therapies that may emerge; Potential product liability claims; Our dependency on third-party manufacturers to successfully, and timely, supply or manufacture our drug candidates

BUSINESS

BUSINESS Our Business Summary We are a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs for hard-to-treat cancers and viruses. We have three core technologies, each of which have had one or more drugs successfully complete a Phase 1 clinical trial, based substantially on discoveries made at and licensed from the University of Texas MD Anderson Cancer Center (MD Anderson) in Houston, Texas. Three of our six drug candidates have shown human activity in clinical trials and are currently or have been in Phase 1B/2 or Phase 2 clinical trials. Since our inception, our drugs have completed, are currently in, or have been permitted to proceed in thirteen clinical trials. Annamycin is our lead molecule and is in three Phase 1B/2 clinical trials - one for treating Acute Myeloid Leukemia (AML) and two for treating Soft Tissue Sarcoma metastasized to the lungs (STS lung metastases, STS lung mets, or Advanced STS). One of our core management beliefs is that anthracyclines represent the most important treatment for AML and Advanced STS, and we believe Annamycin may, for the first time ever, allow a majority of these patients to benefit from this treatment. This belief leads us to currently focus mainly on the development of Annamycin. Our Core Technologies Our core technologies consist of the following programs: a) Annamycin or L-Annamycin is a "next generation" anthracycline (one of the most common classes of chemotherapy), designed to be different than currently approved anthracyclines, which are limited in utility because of cardiotoxicity risks and their susceptibility to multidrug resistance mechanisms. Annamycin was designed to avoid multidrug resistance and to be non-cardiotoxic and has shown no cardiotoxicity in subjects treated in clinical trials to date. Furthermore, we have demonstrated safe dosing beyond the dose limitations imposed by regulatory authorities upon currently prescribed anthracyclines due to thei

View Full Filing

View this 10-K filing on SEC EDGAR